Objective: To discuss the clinical efficacy of Fuzheng Yiliu decoction with ultrasound introduction as an adjuvant treatment for primary liver cancer and its influence on serum golgi glycoprotein-73(GP-73) and glypican-3(GPC-3). Method: One hundred and twenty primary liver cancer patients were included in the study. According to different therapeutic methods

patients were randomly divided into the control group and treatment group

60 cases in each group. In the control group

patients were treated with hepatic arterial chemoembolization. Based on the treatment of the control group

patients in treatment group were treated with additional Fuzheng Yiliu decoction with ultrasound introduction(1 time/d) 3 days after surgery in control group

for 12 continuous weeks. Changes of main symptoms

liver function indexes and T lymphoid subgroups were compared before and after treatment. Levels of GP-73 and GPC3 in the serum of both groups were detected. Result: The total effective rate of the treatment group was 86.67%

significantly higher than 58.33% in the control group after treatment(P<0.05). Main symptoms and liver function indexes alanine aminotransferase(ALT)

aspartate amino transferase(AST)

γ-glutamine(γ-GT) and total bilirubin(TBIL) in the treatment group were significantly lower than those of the control group after treatment(P<0.01). The levels of CD3+

CD4+and CD4+/CD8+ in the treatment group were higher than those of the control group after treatment

while the level of CD8+ in the treatment group was lower than that in control group(P<0.01). After treatment

the levels of GP-73 and GPC3 in the serum of the treatment group were significantly lower than those in the control group

with statistical significance(P<0.01). Conclusion: Fuzheng Yiliu decoction with ultrasound introduction as an adjuvant treatment for primary liver cancer could evidently improve the clinical symptoms and quality of life

inhibit serum levels of GP-73 and GPC3

and improve immune and liver functions.